Orchestra BioMed Holdings (OBIO) Notes Payables (2022)
Orchestra BioMed Holdings (OBIO) posted quarterly Notes Payables of $2.1 million for Q4 2022, up 1292.67% year-over-year from $150000.0 in Q4 2021, and up 1292.67% quarter-over-quarter from $150000.0 in Q4 2021.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Notes Payables (2022) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Notes Payables for 2 consecutive years, with $2.1 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Notes Payables rose 1292.67% year-over-year to $2.1 million; the TTM figure through Dec 2022 stood at $2.1 million (up 1292.67% YoY), while the FY2022 annual figure was $2.1 million, up 1292.67% from the prior year.
- Notes Payables improved to $2.1 million in Q4 2022 per OBIO's latest filing, from $150000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $2.1 million in Q4 2022 and bottomed at $150000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 |